QO
QOL.STU SOL S.p.A
- Market cap
- EUR 5.50B
- P/E
- 31.7x
- P/B
- 4.57x
- ROE
- 14.1%
- Dividend yield
- 0.69%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is QOL.STU undervalued?
Graham numberQOL.STU trades 153.8% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
SOL S.p.A fundamental analysis
No fundamental analysis for SOL S.p.A yet.
SOL S.p.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About SOL S.p.A
SOL S.p.A. engages in the applied research, production, and marketing of technical and medical gases in Italy and internationally. The company offers oxygen, nitrogen, argon, hydrogen, carbon and sulphur dioxide, acetylene, nitrous oxide, gas mixtures, high purity gases, food gases, and gaseous and liquid helium; gas for electronics; and ammonia and combustible gases for industrial use and liquefied natural gas. It also provides oxygen therapy, home mechanical ventilation, a…
Full company profileSOL S.p.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
SOL S.p.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 689M | 703M | 757M | 834M | 904M | 974M | 1.11B | 1.38B | 1.49B | 1.61B | 1.87B |
| Gross Profit | 144M | 311M | 325M | 362M | 408M | 459M | 484M | 504M | 1.08B | 1.21B | 1.43B |
| Operating Income | 61.5M | 75.0M | 68.0M | 82.9M | 89.9M | 130M | 126M | 109M | 190M | 208M | 284M |
| EBITDA | - | - | 161M | 178M | 194M | 250M | 253M | 317M | 369M | 391M | 466M |
| Net Income | 32.4M | 44.1M | 40.2M | 51.9M | 49.3M | 103M | 89.5M | 134M | 146M | 148M | 166M |
| EPS | - | - | 0.44 | 0.57 | 0.54 | 1.14 | 0.99 | 1.47 | 1.61 | 1.63 | 1.83 |
| Balance Sheet | |||||||||||
| Total Assets | 960M | 1.02B | 1.06B | 1.11B | 1.25B | 1.41B | 1.44B | 1.72B | 1.94B | 2.14B | 2.56B |
| Total Liabilities | 502M | 526M | 554M | 566M | 675M | 751M | 723M | 856M | 966M | 1.06B | 1.32B |
| Shareholders' Equity | 443M | 472M | 490M | 528M | 561M | 636M | 698M | 821M | 929M | 1.03B | 1.18B |
| Cash & Short-term Investments | 102M | 120M | 117M | 129M | 169M | 269M | 140M | 135M | 206M | 232M | 287M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 92.7M | 118M | 137M | 133M | 186M | 210M | 193M | 215M | 270M | 297M | - |
| Capital Expenditure | 84.7M | 104M | 93.7M | 94.7M | 97.7M | 106M | 123M | 121M | 205M | 246M | 0.00 |
| Free Cash Flow | - | - | 38.8M | 33.3M | 20.1M | 59.1M | 44.8M | 53.7M | 65.1M | 50.9M | - |
| Ratios | |||||||||||
| ROE | 7.3% | 9.3% | 8.2% | 9.8% | 8.8% | 16.2% | 12.8% | 16.3% | 15.7% | 14.4% | 14.1% |
| ROA | 3.4% | 4.3% | 3.8% | 4.7% | 3.9% | 7.3% | 6.2% | 7.8% | 7.5% | 6.9% | 6.5% |
| Net Profit Margin | 4.7% | 6.3% | 5.3% | 6.2% | 5.5% | 10.6% | 8.0% | 9.7% | 9.8% | 9.2% | 8.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
SOL S.p.A dividends
- Dividend yield
- 0.69%
- Forward dividend
- 0.45 EUR
- Payout ratio
- 25.6%
- Ex-dividend date
- May 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | EUR 37.8M | 0.42 | 25.6% |
| 2023 | EUR 33.5M | 0.37 | 23.0% |
| 2022 | EUR 21.8M | 0.24 | 16.3% |
| 2021 | EUR 20.0M | 0.22 | 22.3% |
| 2020 | EUR 22.4M | 0.25 | 21.7% |
| 2019 | EUR 15.9M | 0.18 | 32.2% |
| 2018 | EUR 13.6M | 0.15 | 26.2% |
| 2017 | EUR 13.6M | 0.15 | 33.8% |
| 2016 | EUR 12.4M | - | 28.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns SOL S.p.A
- Insiders 59.98%
- Institutions 20.86%
- Public & others 19.16%
- Shares outstanding 90.7M
- Free float 33.5M
SOL S.p.A company profile
- Company name
- SOL S.p.A
- Ticker
- QOL.STU
- ISIN
- IT0001206769
- Exchange
- Stuttgart Exchange
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 7,015
- Fiscal year end
- December
- Address
- Via Borgazzi, 27, Monza, MI, Italy, 20900
- Phone
- 39 039 23961
- Website
- solgroup.com
About SOL S.p.A
SOL S.p.A. engages in the applied research, production, and marketing of technical and medical gases in Italy and internationally. The company offers oxygen, nitrogen, argon, hydrogen, carbon and sulphur dioxide, acetylene, nitrous oxide, gas mixtures, high purity gases, food gases, and gaseous and liquid helium; gas for electronics; and ammonia and combustible gases for industrial use and liquefied natural gas. It also provides oxygen therapy, home mechanical ventilation, and aerosol therapy services, as well as the diagnosis and treatment of respiratory sleep disorders; services for artificial nutrition, insulin therapy with pumps, and immunotherapy, as well as services for the treatment of pain and Parkinson's disease; home healthcare and social care services; telemedicine and digital services; and healthcare aids. In addition, the company provides medical devices; training services; InfoHealth SOLution, a web platform that allows to control plans, coordinate, and manage the activities; electromedical equipment services; hospital hygiene and environmental monitoring services; and ambulance management services. Further, the company designs and develops bio banks; supplies technical gases; offers pre-and post-natal diagnostic screening services; develops diagnostic systems; researches, develops, produces, and markets products for research, diagnosis, and clinical application in the hospital, environmental, veterinary, and food sectors; and bioshipping services, as well as provides transfer, storage, and handling services of biological samples. Its products are used in the chemical, electronics, iron and steel, metal, engineering and foodstuff industries, as well as in environmental protection, and research and healthcare sectors. SOL S.p.A. was founded in 1927 and is headquartered in Monza, Italy. SOL S.p.A. is a subsidiary of Gas And Technologies World B.V.
SOL S.p.A management
7- Engineer Aldo Fumagalli RomarioChairman, Co-CEO & MD · born 1958
- Mr. Marco AnnoniDeputy Chairman, Co-CEO & MD · born 1961
- Mr. Giulio Fumagalli RomarioDirector of Legal & Corporate Affairs and Director · born 1964
- Mr. Giovanni AnnoniDirector of Information Systems Organisation & Director · born 1959
- Mr. Marco FilippiCFO & Manager
- Daniele ForniGeneral Director
- Claudio GarbelliniGeneral Director